35 Burst results for "Gilead Sciences"

Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir

Bloomberg Daybreak: Asia

00:12 sec | 6 months ago

Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir

"Gilead Science has reported a revenue jump of 17% that was driven in large part by sales of the code. 19 treatment room disappear. Even so, Kelly had chairs right now down about

Gilead Science Kelly
Covid: US gives full approval for antiviral Remdesivir drug

Balance of Power

01:40 min | 6 months ago

Covid: US gives full approval for antiviral Remdesivir drug

"A Corona virus being a vaccine being available by year end. And yesterday, the FDA of granted its first approval for a treatment, not a vaccine, but a treatment room disappear to Gillian. Scarlett Foods here with some of the details, and, of course, from disappear is one of the treatments that President Trump was given. After he was diagnosed. We saw Gilead Sciences, the company gap higher at the open, rising as much as 4.9%. This is a drug that was originally developed to treat Ebola, and it's now become the first covert drug to get FDA formal approval before that it was available. Under emergency used authorization. So Gilly, I can now move forward with marketing the drug, The new brand name will be victory. I'm not sure why they're changing in. There must be something more to that. But given that everyone knows that, as from disappear, it's a bit of a puzzle to me. Gillian had said it would charge US hospitals about $3100 for most patients now in terms of the numbers, analysts estimate 2020 sales will be about $2.2 billion. Cos. Expected to sell 1.5 million doses this year. One blockbuster drug, of course, can make a huge difference for biotech firm and Gillian will need it because it's getting a lower return from its research and development. Then some of its peers only 40% versus a 42% at Vertex and Bio Marin. Now the FDA approved and disappear for emergency used back on May 1st. But if you look at the stock price, it actually hasn't done that. Well. It's fallen about 23%. Sadie Group says that Gilead has first mover advantage. But that only goes so far because The drug will provide a short term boost for revenue. But sales were actually taper off in the second half, when there's more competition from vaccines and anybody treatments are in development right now make so much the scarlet food for that

FDA Gillian Gilead Sciences President Trump Scarlett Foods United States Ebola Gilly Bio Marin Gilead Sadie Group
"gilead sciences" Discussed on Bloomberg Radio New York

Bloomberg Radio New York

01:38 min | 6 months ago

"gilead sciences" Discussed on Bloomberg Radio New York

"Over to Denise Pellegrini, Rico. Hey, Denise. Thank you, Carolyn Powell. We have a coded curfew going up in Chicago tomorrow Nightmare. Lori Lightfoot, also saying after a second surge there in the second city, she's clamping down on bars as well. Bars don't operate with the food license will no longer He permitted to serve customers inside. And in Ohio Governor Mike DeWine pleading for people to take coronavirus seriously, then introducing former New Jersey governor Chris Christie, who is, you know, contracted the virus after working at the White House, I want everybody out there who's listening to understand. That this is one of the most Unpredictable random. And brutal viruses you'll ever see. In time. The Food and Drug Administration has just approved Gilead Sciences. Antiviral rendez over for general treatment. Red Flag warnings up in six states including Colorado for fire firefighters chasing this so called East Troublesome fire. It's jumped the Continental divide and Governor Jared Pulis in Colorado, ordering some people out of the area as this park residents have been asked to evacuate a major community. And in Washington, House Speaker Nancy Pelosi says progress is being made unstinting Ulus talks between Democrats and Republicans, please that we have reached a point where we at least You still have that They still haven't completely signed off on it. But I think we're just about there. And live coverage of the presidential debate coming up here on Bloomberg Radio's starting at 8 30 with David.

Denise Pellegrini Food and Drug Administration Lori Lightfoot Colorado Carolyn Powell Jared Pulis Gilead Sciences Nancy Pelosi Chris Christie Red Flag Chicago Mike DeWine White House Bloomberg Radio Ohio New Jersey Washington David
"gilead sciences" Discussed on WBZ NewsRadio 1030

WBZ NewsRadio 1030

03:47 min | 6 months ago

"gilead sciences" Discussed on WBZ NewsRadio 1030

"Wednesday Thursday Windy, sunny, high 63 sticking in the sixties Friday so No, really cold weather in sight. There isn't a big change yet. Joe Biden is in Miami today for a campaign event there. Of course, he and Jill Dr Jill Biden both tested negative for Corona virus, so he is able to a campaign to get out on the campaign trail. The former vice president and Senator Kamila Harris, are on the road this week as well, insisting that they will be closely adhering to local safety guidelines. The president's covert diagnosis brings his campaigning to a halt for Joe Biden. It's full steam ahead, but Biden is Inging his tone, pulling his negative ads and tempering his attack, So I don't want to be a Attacking the president and the first lady, now the former vice president, testing negative Sunday after two other negative results on Friday. By the way, the vice presidential debate is on As of now, that is set for October. 7th. We will broadcast that live again for you here. Just asked your smart speaker to play us. We're on the I heart radio app. We're on all platforms now. Double BBC news radio, Your tried and true favorite for decades and we appreciate your loyalty. More than you know. All right, we're coming up on 1 37. The Patriots leaving town on a jet plane make it to all because a cove it double BBC's Jim McKay is more on their journey to Kansas City for tonight's Game. One plane leaving Providence and the other here from Logan today, as the Pats had west to Casey split up because of what else? Covert 19 Patriots quarterback Cam Newton testing positive over the weekend, postponing the Sunday afternoon match up and sending everything into a tailspin. After rounds of negative test the entire team leaving town today on two separate planes separating players who practice near Cam Newton and those who don't know the Pats play tonight at 705 against Patrick Mahomes and the chief's Brian Hoyer will be under center for the past. Reporting from Logan, Jim McKay W B Z Boston's news radio. Lawsuit against Major League Baseball filed by minor league players is rounding third and heading home without comment. The Supreme Court has rejected Major League baseball's appeal of a class action lawsuit. Minor league players in Arizona, California and Florida sued, alleging they're being paid less than minimum wage. The players first took legal action against major league teams in early 2014, claiming most of them earn less than $7500 annually in violation of several laws. That was CBS. Jim Priscilla. And Right now we're going to say hello to Mona Rivera over at Bloomberg Business News, Business News and Good afternoon Laurie in the missile, the health issues facing the White House, Wall Street continues to cling toe hopes for more fiscal stimulus, so the Dow is up 372 points one and a third percent. The S and P is up nearly 1.4%. While the NASDAQ's one and three quarter per cent higher. Regeneron Pharmaceuticals is having its best day in nearly seven months. Shares are up more than 7% in the aftermath of President Trump, receiving the company's antibody cocktail to treat his illness. President is also being treated with Rendez severe in the maker of that drug. Gilead Sciences is up 2.5% I'm on a Rivera blundering business on W. B. C. Boston's NewsRadio covering Brockton. Still weak Field Somerville Way Know where you Live? W b z Boston's NewsRadio Hi This is Kevin Keeler from Brady son rooms. I was talking with a customer the other day, and they were telling me how they have saved a lot of money on heating bills. Because of their Brady sunroom. It is open to their house. The whole first floor at a comfortable 70 degrees all day long. The heat never even kicks on until nighttime,.

Jill Dr Jill Biden vice president Jim McKay BBC Boston Pats Mona Rivera Logan Patriots President Trump Cam Newton Miami Regeneron Pharmaceuticals Senator Kamila Harris Major League Jim Priscilla Brian Hoyer CBS
Trump receiving remdesivir antiviral drug as part of experimental treatment

Weekend Edition Saturday

00:50 sec | 6 months ago

Trump receiving remdesivir antiviral drug as part of experimental treatment

"Trump's physicians as the president is being treated with room to severe. NPR's Joe Palka reports. That's a drug usually reserved for hospitalized Covad 19 patients who are quite ill. Rendez severe, is an antiviral drug made by Gilead Sciences. It's administered intravenously, typically to hospitalize patients for five days, 10 days for sicker patients. So far, the best medical evidence suggests the drug reduces hospital stays by about four days. It's not clear if it prevents deaths from Cove in 19. An expert panel, convened by the National Institutes of Health concluded there are insufficient data to recommend either for or against the use of ram best severe in patients with mild or moderate cove in 19. The president also received an experimental monoclonal antibody therapy made by the company. Regeneron

President Trump Joe Palka Gilead Sciences Cove National Institutes Of Health Donald Trump NPR
Merck to Invest $1 Billion in Seattle Genetics

Bloomberg Surveillance

00:54 sec | 7 months ago

Merck to Invest $1 Billion in Seattle Genetics

"Which is more than doubled up 106%. This company makes the cancer drug traditional V had accepted a $21 billion takeover offer from Gilead Sciences now tried. L ve won. US clears in April to treat triple negative breast cancer and immuno medics plans to seek broader approval later this year. You've also got Merc moving into breast cancer treatments as well. A Seattle genetics up 9% after Merck agreed to invest a billion dollars in the drugmaker. At $200 a share as 33% higher than last week's close. The purchase is part of a Siri's of deals worth as much as $4.5 billion for two breast cancer drives, and indeed one of them Treats triple negative breast cancer, so you'll have a competition to Gillian A. Merc in that segment of the drug industry varieties is up.

Gillian A. Merc United States Gilead Sciences Siri Merck Seattle
Dow Jumps As Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of Death

Bloomberg Businessweek

00:30 sec | 10 months ago

Dow Jumps As Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of Death

"That laid Corona virus fears in the stock averages gained 2/3 to nearly 1.5%. The Dow rose 369 the NASDAQ 70 to another record close at 10,006 17. Yes and Pete gaining 33. Those gains followed an analysis of Gilead sciences drug round death severe, which indicates it may have reduced deaths of Corona virus patients by 62%. Dude sent Gillian shares 2% higher and allowed investors to ignore another record increase in cases of the disease. Facebook has been

Gilead Sciences Facebook Gillian Pete
Gilead's remdesivir will cost $3,120 for private insurance

AP 24 Hour News

00:44 sec | 10 months ago

Gilead's remdesivir will cost $3,120 for private insurance

"Has helped reduce the effects of Copan, 19 and some patients will cost thousands from desert here has been shown to shore in the recovery time for seriously ill Cove it 19 patients maker Gilead Sciences says a typical treatment course will cost people under government health programs and the U. S and other rich nations. About $2300. It will be roughly 3100 for those with private insurance in setting the price. Gilead CEO says it had to focus on wide access to the drug and not solely on value to patients. But the cost is being criticized by a consumer group who calls it an outrage and buy a Cleveland clinic doctor who says he'd prefer the government take over production and distributed for free.

Gilead Sciences Copan CEO Cleveland U. S
Gilead's coronavirus treatment remdesivir will cost $3,120 for patients with private insurance

Morning News with Manda Factor and Gregg Hersholt

00:24 sec | 10 months ago

Gilead's coronavirus treatment remdesivir will cost $3,120 for patients with private insurance

"A drug that has been shown to shorten recovery time for severely ill covert patients. Says it's quite a charge $2340 for a typical treatment course for people covered by government health programs in this country. Gilead Sciences announcing the price today for rendez severe. And says the price would be $3120 for patients with private insurance. The

Gilead Sciences
Gilead prices coronavirus drug at $2,340 for rich countries

AP News Radio

00:47 sec | 10 months ago

Gilead prices coronavirus drug at $2,340 for rich countries

"The first drug proven to show a benefit in the corona virus pandemic now has a price tag when disappear has been shown to shorten the recovery time for seriously ill Colby dying teen patients maker Gilead sciences says a typical treatment course will cost people under government health programs in the U. S. and other rich nations about twenty three hundred dollars it'll be roughly thirty one hundred for those with private insurance in setting the price Gilead CEO says it had to focus on a wide access to the drug and not solely on the value to patients but the cost is being criticized by a consumer group who calls it an outrage and by a Cleveland Clinic doctor who says he preferred the government take over production and distributed for free Sager made Ghani Washington

Colby Gilead Sciences Gilead Ceo Sager Ghani Washington Cleveland Clinic
Gilead prices coronavirus drug at $2,340 for rich countries

AP News Radio

00:47 sec | 10 months ago

Gilead prices coronavirus drug at $2,340 for rich countries

"The first drug proven to show a benefit in the corona virus pandemic now has a price tag when disappear has been shown to shorten the recovery time for seriously ill Colby dying teen patients maker Gilead sciences says a typical treatment course will cost people under government health programs in the U. S. and other rich nations about twenty three hundred dollars it'll be roughly thirty one hundred for those with private insurance in setting the price Gilead CEO says it had to focus on a wide access to the drug and not solely on the value to patients but the cost is being criticized by a consumer group who calls it an outrage and by a Cleveland Clinic doctor who says he preferred the government take over production and distributed for free Sager made Ghani Washington

Colby Gilead Sciences Gilead Ceo Sager Ghani Washington Cleveland Clinic
Gilead's $2,340 price for coronavirus drug draws criticism

Charlie Parker

00:13 sec | 10 months ago

Gilead's $2,340 price for coronavirus drug draws criticism

"Room does severe will cost a substantial amount of money the drug's been approved by the FDA for use in treating some coronavirus cases it's maker Gilead sciences says the cost of a five day course of treatment will come to nearly twenty three hundred fifty

FDA Gilead Sciences
Gilead says drug helped moderately ill coronavirus patients

NPR News Now

00:24 sec | 11 months ago

Gilead says drug helped moderately ill coronavirus patients

"California. Biotech firm is reporting some positive results with experimental drug remedies Aveer Gilead Sciences today reporting the drug when given a moderately. Moderately, ill patients hospitalized with covid nineteen shouted improved symptoms so far it's the only drug that's been shown to help. Fight the coronavirus, a large study down recently by the national. Institutes of health also found the drug would shorten recovery time for patients hospitalized with severe

Aveer Gilead Sciences California. Biotech
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

Wait, Wait Don't Tell Me!

00:51 sec | 11 months ago

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

"Of peer reviewed paper confirms earlier findings that the drug room desk severe can help patients hospitalized with covert nineteen recover NPR's Joe Palca reports them disappear is an antiviral drug made by Gilead sciences in February a multicenter trial began comparing ram disappear with a placebo in covert nineteen patients who required hospitalization slightly more than a thousand patients were enrolled in the trial late last month an interim analysis showed the drug was helping those on rent disappear had shorter hospital stays than those on placebo eleven days versus fifteen days the results prompted the food and drug administration to grant emergency use authorization for Rambus severe making it easier for doctors to prescribe it to patients a paper in the New England journal of medicine confirms the earlier results

Joe Palca Gilead Sciences Rambus New England Journal Of Medicin
"gilead sciences" Discussed on WTOP

WTOP

03:24 min | 1 year ago

"gilead sciences" Discussed on WTOP

"Nine thirty eight C. price again whether on the aids and when it breaks chain bridge it remains close to fire department activity police investigation it is blocked between one twenty three chain Bridge Road and canal road there will be no traffic across the bridge for a bit there's an investigation ongoing in north west New Jersey Avenue west bend your second street crash cleared Martin Luther king junior Avenue south west south south capitol street you were still potentially under direction from this earlier accident there is a ceremony today seventeenth street is closed between independence Avenue and constitution Avenue there's a World War two memorial ceremony today new trouble Maryland at ninety five south of four to sixteen the accent along the left side twenty nine north beyond two sixteen we had a reported accident now on to seventy headed north bound into Frederick you approach eighty five Bucky's town pike the crash have been reported in the right lane in blue E. route three south bound his head from Bel Air drive down toward fifty emergency road work and then along the right side of the roadway fifty is in good shape right now both ways between about when the bay bridge earlier than a little delay moving on fifty east out here for ten could just be a slow exit no big issues to speak of yet I think the work is set up north on I. two ninety five to run toward MalcolmX Avenue always causes a little bit of a slowdown so be careful with a great selection of roses hanging baskets and more meadows farms makes mother's day easy this year visit one of the eighteen locations today meadows farms makes gardening easy Jack Taylor WTOP traffic Axios is reporting that dysfunction within the trump administration is undermining the distribution of ram does appear to treat the corona virus Gilead sciences the company that makes.

Maryland Bucky Martin Luther Bel Air Jack Taylor Gilead sciences
The origins of the antiviral drug Remdesivir

Second Opinion

04:45 min | 1 year ago

The origins of the antiviral drug Remdesivir

"Vaccines and medications will be the ultimate weapon used to beat Kovic. Nineteen and there's a giant race to develop the first medications vaccine driven both by Prophet and prestige. The potential market is enormous. This week we learned about the limited effectiveness of a drug called rim disappear made by Gilead Sciences but the story of that drugs development is far more interesting than was reported. The story starts with a universally fatal illness in cats called Feline infectious peritonitis or F-. Ip this nasty disease is caused by a corona virus and is surprisingly common in cats. Who spent a lot of time in shelters or rescue facilities? Dr Neal Peterson is a distinguished professor of veterinary medicine at UC Davis and has spent his professional career beginning in one thousand nine hundred sixty four studying corona viruses in animals particularly in the cat. He tried for years to develop a vaccine for F. I. P. Vaccines have never been highly effective against corona viruses. So this is something that the human Researchers Heaven appreciated. They haven't taken seriously so without a vaccine. That left only the option of medication. Dr Peterson worked collaboratively with Gilead Sciences. To look at their existing compounds for chemicals that might help with F. I. B. and we found two drugs that were highly effective against F- IP virus in tissue culture and a second drug was called rim disappear. This is the drug that this week. Dr Vouch e touted as being a benefit to people infected with Kovin we have had our little pandemic. That's been going on for years and we've been treating patients with basically the same drug having high success rate and nobody has even mentioned that it exists. No one paid any attention to the veterinarian who had great experience with Corona Viruses. Gilead refused to allow him de severe to be made for cats because there was very little money in it gilead was waiting for something really big that could result in treatment for humans and generate significant money. They tested the drug as a treatment for Ebola but it failed so they waited. According to Peterson Gilead was afraid if the drug was approved for and it showed some side effects it could prevent future approval for humans and squelched their chance of making hundreds of millions of dollars so rendez severe sat on the shelf and could not be used for cats with F. I. P. But enter the Chinese who also had a growing problem with F. I. P. in their own cats they saw the potential of the drug rendez severe for cats and they began to produce it themselves and interestingly the scented covertly to pet owners here in the United States but then came cove and the Chinese saw the drugs potential for treating corona viruses in humans and perhaps the rest is now history with the recent trials showing it is moderately successful in treating Cova nineteen and Gilead stocks. Shooting up of course one lesson that might go. Unnoticed are the important gems that lurk in the world of animal science. They had evidence from the TAT. But you see nobody ever uses that. Nobody references those papers from the medical side. They all talk about some experimental bow. Study or some primate infection study but they never mentioned the cat. Human medicine is often unaware of what's happening in animal health. As we now rushed to find a vaccine for cove there are also important lessons. We risk missing. You realize that we've been vaccinating krona viruses in cats and in poultry and swine and even some of the other species for decades. We know all the weaknesses and strengths of vaccines. We've studied Corona virus infection and pathogenesis in detail. Do you ever see anything in the literature? Saying hey the poultry. Industry has been vaccinating for infections bronchitis for decades. They never mentioned any of that stuff. Perhaps this speaks to the enormous importance of the concept of one health. That is the interdependence of all living things.

Dr Neal Peterson Gilead Sciences Kovic Dr Vouch E Ebola Distinguished Professor Uc Davis United States Cova
U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir

Texas Home Improvement

00:21 sec | 1 year ago

U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir

"The FDA is approving a drug that could be used to help patients suffering from covert nineteen fox's Martin Meredith from the White House before he left for camp David the president walking ahead of Gilead sciences to the oval office the FDA granting emergency use of the company's drug room does appear to treat covered ninety patients clinical trials have shown the drug coverage time

FDA Martin Meredith White House David President Trump Gilead Sciences
Remdesivir Shows Promise as a Coronavirus Treatment

Fresh Air

00:36 sec | 1 year ago

Remdesivir Shows Promise as a Coronavirus Treatment

"U. S. regulators will be allowing the emergency use of the first drug that appears to have shown some promise in helping those who develop cope with nineteen recover more quickly president Donald Trump announcing today the food and drug administration has given the green light to the drug when does appear we've been doing work out with the teams at the F. D. A. N. I. H. M. Gilley added for spearheading this public private partnership to make this happen very quickly drug might also be reducing deaths from covert nineteen no that is not yet certain based on the partial results drugmaker Gilead sciences says it will donate its currently available stock is ramping up production to make

Donald Trump H. M. Gilley President Trump Gilead Sciences
FDA allows emergency use of drug for coronavirus

AP News Radio

00:57 sec | 1 year ago

FDA allows emergency use of drug for coronavirus

"Federal regulators will allow emergency use of an experimental drug that appears to help some coronavirus patients recover faster in normal times the food and drug administration require substantial evidence of a drug safety and effectiveness in a public health emergency though we can simply require that a drug's potential benefits outweigh its risks that's what it's doing with Gilead sciences run does appear the first drug shown to help fight covert nineteen it's really a very promising situation president trump announced the emergency authorization in the oval office alongside Gilly add CEO Daniel o'day who says the company is donating its current stocking and ramping up production there are patients out there that can benefit from this medicine today that are hospitalized and we don't want any time to waste no drugs are actually approved for treating the virus and random severe still needs formal approval Sager make ani Washington

Gilead Sciences Donald Trump Gilly Daniel O'day Sager Ani Washington President Trump CEO
FDA allows emergency use of drug for coronavirus

AP News Radio

00:48 sec | 1 year ago

FDA allows emergency use of drug for coronavirus

"In normal times the food and drug administration require substantial evidence of a drug safety and effectiveness in a public health emergency though we can simply required that a drug's potential benefits outweigh its risks that's what it's doing with Gilead sciences rent does appear the first drug shown to help fight covert nineteen it's really a very promising situation president trump announced the emergency authorization in the oval office alongside Gilly add CEO Daniel o'day who says the company is donating its current stocking and ramping up production there are patients out there that can benefit from this medicine today that are hospitalized and we don't want any time to waste no drugs are actually approved for treating the virus and random severe still needs formal approval Sager made Connie Washington

Donald Trump Gilly Daniel O'day Sager Connie Washington Gilead Sciences President Trump CEO
Fauci voices optimism about remdesivir as treatment for COVID-19 infection

WTOP 24 Hour News

01:46 min | 1 year ago

Fauci voices optimism about remdesivir as treatment for COVID-19 infection

"CBS is Dr Tara rule with more on a drug that Dr Anthony Fauci said could block the corona virus yes if your antivirus work better we know earlier in the disease process when the virus is replicating now it's important to know room disappear is an IV drug it must be given to hospitalized patients in the hospital as an infusion usually over several days CBS news update on that Piper and doctor found she tells NBC's today show the food and drug administration is working on emergency approval for that drug it's going to be really quickly I was speaking with the commissioner of the FDA yesterday evening last night and he's moving along very quickly they have not made a final decision yet they have not announced it but I would project that we're going to be seeing that reasonably soon meantime the C. E. O. of Gilead sciences which makes Renda severe says the company's existing supply could cover at least one hundred forty thousand treatment courses that estimate is based on a ten day treatments with the drug but another trial finds that five days of treatment appears just as effective and that could effectively double the supply Steve Morris is the director of broadcast engineering for CBS he credits run does appear for with saving his life after he got covert nineteen back in mid March by three main symptoms were cough fever and difficulty breathing went to the urgent care twice and was basically sent home after a X. ray was taken of my lungs that came back negative a week later Boris was in a New Jersey hospital where he continued to get sicker and was about to be put on a ventilator but that's when he was entered into a trial for rent a severe and by March twenty sixth his fever subsided two days later he was out of icy you know ventrally well enough to

CBS Dr Anthony Fauci Piper NBC Commissioner FDA E. O. Gilead Sciences Renda Steve Morris Director Fever Boris New Jersey Hospital
"gilead sciences" Discussed on WSJ What's News

WSJ What's News

03:38 min | 1 year ago

"gilead sciences" Discussed on WSJ What's News

"After Federal Reserve Chair. Jerome Powell made it clear. The central bank is in no hurry to end. Its economic stimulus measures. All major indexes were up. We'll talk more about the Fed and the overall economy later in the show with regards to that drug treatment. Shares of Gilead Sciences closed up five point seven percent after it reported that patients taking its antiviral drug rim. Desa VIR showed a speedier recovery than patients taking a placebo in a large study funded by the US government our health reporter Joe Walker has more details. People have been watching this trial really closely because it's a large study comparing this drug to placebo and it's sort of the gold standard for the way to do clinical trials. So the idea is. We think that it's the first and best sort of look at whether this truck really works treating Cova nineteen and if it does it could become the first road proven to actually be effective against this disease. A separate study of the drug out of China posted negative results today but researchers there say they needed more testing. Their trial was shut down early. Because it was hard to recruit subjects as the pandemic slowed analysts are still cautioning that the drug is unlikely to be a silver bullet. Obviously it would be really great if this works and cove in nineteen. I think the expectation though at this point is that if it does work. It's not the type of thing that everybody would get. If you've got the virus you know. It's an intravenously administered drug for people who are hospitalized so we can really make a difference in in helping people who are very very sick but isn't sort of the vaccine. It's not a pill so I would just say. Take some caution. There in terms of expectations for the magnitude of its impact corporations have been reporting first-quarter earnings all week shares of alphabet. Google's parent company climbed nearly ten percent after it posted strong results. Facebook shares rose more than six percent ahead of its earnings report which came after the bell. Deputy Business Editor George. Stall says so far. The impact of the corona virus on business is largely falling into two main camps broadly. Speaking we've seen stronger results from companies that service consumers in their homes Netflix saw a surge in new subscribers to its streaming video service consumer product makers benefited from people stockpiling up on the cities and even a company like Hasbro which makes traditional board games like connect four monopoly. An operation reported a twenty five percent jump in sales of such products not surprisingly companies that we depend on when we leave the house have struggled talking about automakers the airline industry the tourism industry and the question going forward is how temporary are some of these shifts that we are seeing in consumer patterns and which may be longer lasting. Boeing. Ceo says the pandemic dealt a body blow to its business aerospace giant burned through four point seven billion dollars in cash in the first quarter. That's less than analysts. Had expected but Boeing is now planning to cut thousands of jobs about ten percent of its workforce and take on more debt. The trump administration has placed five of Amazon's foreign platforms on a list of notorious markets. The US believes are facilitating the sale of counterfeit and pirated goods. That includes Amazon's domains in Canada France Germany India and the UK Amazon is calling the designation a purely political act. President trump has frequently criticised.

US Federal Reserve Chair Amazon Boeing Jerome Powell Gilead Sciences Desa VIR Fed Cova Facebook Google trump Netflix Business Editor Hasbro Stall Joe Walker President
"gilead sciences" Discussed on Biz Talk Radio

Biz Talk Radio

01:37 min | 1 year ago

"gilead sciences" Discussed on Biz Talk Radio

"Two thousand was down the equipping of two hundred and seventy down points the mid caps with down the equivalent four hundred Dow points new yearly lows in the market six hundred and fifty yearly lows we just came off the yearly highs in the industry no really new yearly highs in the market let's see how did Gilead sciences they may have some sort of they're working on some sort of something or other a bunch of bond funds yeah bond fund after bond funds division two homeless then I see a couple of smaller biotechs no thank you at all T. J. maxx new high on their earnings got a mention that one I get all my Scooby doo socks there and one more big biotech Regeneron pharmaceuticals I know I'm done so let me be a little repetitive here we explain to you the facts of of what's going on we try to add one plus one equal to about Hey everybody's getting all these mass that means they're worried and guess what by no coincidence all the travel related stocks the restaurants about people going out all that stuff you would think people would maybe.

Gilead sciences T. J.
"gilead sciences" Discussed on WCBM 680 AM

WCBM 680 AM

01:48 min | 2 years ago

"gilead sciences" Discussed on WCBM 680 AM

"Two six six eighty four ten ninety two six hundred. Eighty let me give you folks an idea and I rarely say, this but I want you to write this down because this is something I think will fit a lot of people's. Portfolios There's an investment. It's what's called a closed and mutual fund it's a mutual fund, portfolio but it trades on the stock exchange so you it by individual shares of AT and t. your IBM okay And in it is all the. Top healthcare stocks this is, called Tekla t k LA Tekla healthcare. Opportunities to symbol is t h q I repeat that t h. Hugh The top Canada portfolio Johnson and Johnson is number one. Followed by United health group Gilead sciences, two major biotech company Pfizer Abbott labs Merck, Amgen Medtronic Abby and cell gene and other by check the ran at the top ten. So when you buy into this. Portfolio you you basically by the, top healthcare companies which is a group that's been pushed down, a little bit for a number of reasons healthcare is here to stay folks you can't get away from healthcare and we think along with. A lot of other outside experts it's an opinion that this sector can move fifteen to. Twenty percent the next twelve months But here's to beautiful things about investing this way Number one All these closed end funds every day at, market close we calculate a net. Asset value all, that is is we hypothetically? Liquidate stocks and if we paid off all, the shareholders what would? You, get well the net asset value of Tekla healthcare.

Tekla healthcare Johnson AT Gilead sciences Pfizer Abbott Medtronic Hugh Amgen IBM Merck Twenty percent twelve months
"gilead sciences" Discussed on Bloomberg Radio New York

Bloomberg Radio New York

05:55 min | 2 years ago

"gilead sciences" Discussed on Bloomberg Radio New York

"Afternoon Carol Massar along with Jason Kelly just a reminder we're. Expecting some news from the White House saw regarding that meeting. With the president, immigration, traits will take you there as soon as it begins in the meantime Jason we did see the equity markets take higher, three hundred eighty six names. In the s. and p. five hundred higher today hundred seventeen lower to unchanged so. Obviously a more bullish slant certainly going into the. Last half hour of trading he definitely accelerated toward the end of the day and as we've been talking, about a lot. Of earnings, coming out Qualcomm breaking across the terminal right. Now three q. adjusted third quarter I. Should say adjusted EPS at one dollars one cents the estimate at seventy cents Qualcomm is going to buy back up to thirty billion dollars of shares and. Notably going to terminate its packed to, buy inex- p when that agreement expires at the end of the day today Qualcomm gaining about seven point Seven percent annex XP falling almost four percent as that deal was terminated all. Rights isn't big news I, just. Thought I think. Gilead also just crossing the Bloomberg terminal Gilead sciences big player in the biotech center. Sector Gilead second quarter Justice GPS a dollar ninety one the. Estimate a dollar, fifty, six and the CEO John f. Milligan stepping down to stay through the end of the year but stepping down at that, company so that's interesting revenue. By the way big beat five point six billion for the second quarter versus an. Estimated almost five point two billion dollars a change. In the executive suite right now Gilead shares just up about one third of one percent and you mentioned, that Qualcomm buyback. What up, to thirty billion dollars billion dollars yes that's. A big by Gilead I will I. Will point out that just as that headline was breaking I was looking at Twitter and drew Armstrong who is our ase healthcare guy here at Bloomberg all. He says holy smokes Gilead CEO is, out which makes me think This was not expected always. Smokes, usually means that's the technical term, technical term for I did not see that coming we should point out. Still coming is Facebook earnings. So as soon, as that crosses the Bloomberg terminal will bring that, to you and also some comments coming to from. President. Trump when it, comes to trade with the, EU AT and t. by the way your number four biggest decline in the s. and p. five hundred down about four, and a half percent twenty four. Hours ago we were talking a lot, about AT and t.. Because they came out with their results at stock sinking to a. Six year low unflagging wireless growth I put that out because, we did see that stock trade higher in the after, hours and lower and lower in. The after hours and lower today but I. Did, also see a story on. The Bloomberg. That talked about us Alison muddled parts at eighteen kind of. Detracting from some strong numbers at the company, so maybe think about it another headline crossing right, now so many, coming across. Carol Mattel cutting over twenty two hundred position They are planning. To sail of manufacturing sites in Mexico their earnings coming out an adjusted loss for sheriff fifty six cents the estimated loss according to analysts was expected to be thirty one cents so some big news coming, out of Mattel that of course following some surprisingly good numbers if I recall this correctly from Hasbro earlier this earlier this week. Head expected those numbers to maybe be a little bit worse given the demise of toys r. us that we have reported quite robustly on both traded. Higher it took Mattel higher but obviously that's not playing at Mattel down about one third of one percent Facebook crossing the Bloomberg terminal let's get to. Those numbers second quarter monthly active users one number we like to highlight two point twenty three billion maybe a little light the estimate out there was two point. Five billion so we'll see. How investors kind of filter, through that number where they. Think, that's a bit of a disappointment Second quarter EPS a. Buck seventy four two pennies better than. Wall Street was forecasting second quarter revenue thirteen point twenty three billion again a, little light thirteen point thirty three, billion was. The number that Wall Street was expecting and a quick check on the. Trade Jason the after our stock is out, nine percent yes, and as this tends to. Happen dragging down some other stocks as well Twitter and snap also, declining presumably on those Facebook number so in the exact opposite. Way that we saw Google alphabet lift a lot of tech shares in the wake of its. Results Facebook not just, dragging down its own shares but others as well yeah exactly I'm just looking at our live blog I. Love to do this when we've got earning, Selena Wang. Weighing in on those Facebook earnings she's our tech reporter she, says revenue monthly active. Users daily active users all missing estimates, she says. This is a rare occurrence for a company that has consistently beat analysts and investor expectations hints that explains a Big time Jason that. Stock being down in the. After hours down about nine, ten percent here and this as we've been. Talking about was. A company that people were looking so closely at. As the day. Went on and very very disappointing numbers by almost every measure coming out of Facebook will also obviously. Be looking for a lot more color but, what. You just brought up from Selena's, very interesting and we want to know. About Instagram because people have been focusing much more on. Instagram the growth they're tapping into younger users and maybe to some extent Bloomberg BusinessWeek doing great story about this and have been. Covering, it in that maybe this is to, some extent the future. Our, future. Growth for Facebook so we'll hopefully dig. Into that in just a moment again Facebook shares down about nine percent here in the after. Hours to bring up. The vix, I'm curious, to see, no, surprise Vicks down about two. Point one, percent of stocks rallied on Wall Street the vix closing on this Wednesday, at twelve point fifteen this is Bloomberg Right.

Facebook Bloomberg Qualcomm Jason Kelly Mattel Twitter president CEO Gilead sciences Selena Wang Carol Mattel White House AT Carol Massar Instagram Milligan Google Vicks Trump
"gilead sciences" Discussed on AM 920 The Answer

AM 920 The Answer

02:37 min | 3 years ago

"gilead sciences" Discussed on AM 920 The Answer

"Next three to five years to grow at a pace a county in that ballpark it it seems to me that this is kind of a kind of an easy call i would continue to hold sale gene in fact if you think of another one of its biotechnology peers gilead sciences l d on the ticker there it's selling in a pe of nine point six two pg still below one you know if if you look at what's been working lately like an amazon with a p e of two fifty seven and a pg that's over five times people are buying that like crazy and basically selling sale gene selling gilead i think you see that from time to time though we we see the when something's hot everybody's jumping in when something's not they want to sell it but they're not looking at the fundamentals absolute as much as maybe we should that's exactly what i'm saying here the fundamentals for this company the fundamentals for many of the other companies in biotechnology look so much more attractive than than information technology especially that was fang stocks we hear talk about and by the way if you look at what's happened year to date dj this is something you and i talked about yesterday we've got growth type companies that's and p five hundred growth index is up over five percent year to date while value which generally focuses more on dividends and other fundamentals lower prices things of that nature is down slightly on the year there's a seven percent differential between growth stocks and value stocks in two thousand eighteen while the market is only up one point three five percent to me there's there's a pretty significant disconnect between what investors are doing in what seems to make sense i only say that because it actually adds to the case in my opinion when it comes to a company like cell gene yeah i appreciate your listening i thank you for the question and if i if you're listening to me then i'm telling you to hang on to cell gene in fact it seems bible to me at this point yeah so there you have it that's my opinion i hope it works out for you works out for me too because i invest in the same things so let's move on.

amazon gilead sciences three five percent seven percent five percent five years
"gilead sciences" Discussed on KGO 810

KGO 810

01:57 min | 3 years ago

"gilead sciences" Discussed on KGO 810

"Most people i think the and this is if you're really prepared you don't you can listen well to what the other person says and then be ready to respond but so many people youth and tell our thinking about what they're going to say response and instead of what the person sent sometime miss tremendous opportunities to comment on a on a contradiction or stumble or something like that and in say something that's uh that's nice but not in a in a in a mean way you know i mean that's like um i can help people that if you need some help with and then and and and they want to see that you don't want to tear the throat out the other person because you're naso naturally superior that you wouldn't you wouldn't lower yourself to that i'm serious you'd i just ate i don't know man i i think about people that um that's why i like mark cuban marquee marketbound that is a pressing i'd states but as a guy it's worth three or four billion dollars he knows how to talk to people like the real people i mean the apparently the the dallas mavericks that this team the advocate in a temporary denny's has he made a whole no no he's yeah he does have a temper and he said he to heal but lies the rub some people the wrong way at high so um but by the way so cagey as woman the week of an autumn our conference is coming i thought to antiflood from i gilead sciences in that would ease the vp of public affairs very good conversation we were talking about women and the mistakes they might make on they're trying to get that promotion of that raise and uh just one of the many many women that are gonna be at the conference i will be there in the morning mc'ing one of the session so our will come at a pause also we have our ronald's report we also have alternative news vagueness four tickets to go she journey into a leopard and we have uh in the uh six o'clock we're going to give away tickets to go see the gogos and or of the human league so me over good luck craft all coming up here hey exempt traffic from the children autobody traffic does get got that accident on the peninsula rarely say wanna ones better than thaad but it is in.

"gilead sciences" Discussed on KGO 810

KGO 810

02:18 min | 3 years ago

"gilead sciences" Discussed on KGO 810

"The bear score kits do as well for every golden bear's assist gilead sciences will donate fifty dollars to the boys and girls club the oakland dr acumen j john did start for the barisa especially defensively as they lead arizona 1210 1132 remaining in the first half as a arizona you look at the stats his while they were the official 5 of 8 from the field but they're 7 turnovers so half of their possessions nearly half turned of all over welfare yup yes to that you have stalled but it again the nokia will taken advantage those jobs and got eight points off the turnovers but the other issue or less lonely up four points out of your awkward in in old in and so you're going to have to work on a halffull office t so far so good near the defense of peace we talked about so arizona with the rock bears leading by two bear staying at two threes only want to pack it in the sean winston is coming for the rangers 6 to freshman from lake balboa some california and a 3point shot by parker jackson cartwright is good and also of foul on the play the file is on hold it must be on arizona again the it fell to the foul puddles on eighteen apparently the ellen so we count the basket to give arizona there firstly thirteen twelve but uh the bears get the ball back in eighteen gets his first of personal fouls as a mistake there by winston bf you have to know where parker jackson cartwright is these by far and away the best 3point shooting cheers kalman switch out by dussan rich but they he goes back into paint dennis smith now contest calment angles to his left give it a kingsley elbow right to jump shot colder there well maybe things that he's on the record and his game of the box well the first served for everything if you keep doing it that way and the two three look again the ball to eight at the elbow gaetan pull a problem fifty over kingsley good and that's the difference between the audrey eight and in most big many college basketball he can make that show a regular very very smooth very very good religious the.

gilead sciences arizona nokia sean winston rangers lake balboa california parker jackson cartwright official ellen winston bf dennis smith basketball fifty dollars
"gilead sciences" Discussed on WGIR-AM

WGIR-AM

02:06 min | 3 years ago

"gilead sciences" Discussed on WGIR-AM

"The cure for cancer is getting closer and closer gilead sciences eleven billion dollar bet on buying kate pharmaceutical inc is poised to pay off with the approval on wednesday of kites flagship cell therapy treatment for adults with advanced limp a high lymphoma hi everybody it's very in chuck with you covering a story we've talked about this in the past but yesterday we got major news as it relates to this procedure i would even call it a drug so much as a procedure yeah this is another one of these what they call car t procedures that effectively allows cells to develop antibodies to fight cancer on their own they manipulate the cells they've rian they they take your blood cells out of your body they reengineer them then they put them back into your body so they can fight the limpopo and novartis had come out with one of these in august four or form of leukemia that is common in children and young adults this one here is four adults who have certain kinds of advanced lymphoma what you see from a lot of these carty treatments right now is there primarily targeting cancers of the border that are associated with the blood wound fohmann leukemia in the reason for that is they can't really targets certain parts of the body right now so they have to target kind of what it's flowing in and where where it ends up going um but you know what's interesting here's you know these types of treatments or long with no other types of immune a therapy and so forth they are the future of cancer treatment it will your view of what cancer treatment is heavy twenty thirty years from now raged drastically different from today have you manage the cost associated with it though because i know hit novartis has a therapy that similar to this cost four hundred in seventy five thousand dollars gilead has a caught the the one we're talking about the the list price is three hundred and seventy three thousand dollars and if you're if it's your mother fits your son that has this lymphoma you want that drug right you don't care what cost so in this is this is where so much of the challenges because let's let's look at some things just the.

cancer limpopo leukemia lymphoma gilead sciences kate pharmaceutical inc novartis carty seventy three thousand dollars seventy five thousand dollars eleven billion dollar twenty thirty years
"gilead sciences" Discussed on BizTalk Radio

BizTalk Radio

02:36 min | 3 years ago

"gilead sciences" Discussed on BizTalk Radio

"What's against to invest was that trump gallic hop i'm your host thanks for being with us today at this friday we are pretape in the show in the last hour the market and another good day today in the market we were up in futures we will up out of the get go and we just sitting there on hinai kansas probably gonna be light of volume as we head into the labor day weekend but good tone not a lot to complain about biotech's again off today they started off slowing they've been bought up here the big money is jump in all over biotech in the sympathizer move on tight pharmaceuticals being bought for eleven billion dollars and they don't have a sales yet on antidrug i do believe they have these some of these biotech's get these fees consulting type fees and i do believe they have some of that but leave no doubt the company loses a ton of money and gilead sciences this thinking that they're making a good bet on this new cancer i guess award this therapy you can go read up about tight just like the word kite pharmaceuticals and what the new cancer therapy is supposedly i mean i've been reading a little bit i'm going to read a lot more of the weekend so i know a lot about it supposedly it's the shape of things the com and it really along gates are life span based on august tcells which i know absolutely nothing about but i will know everything about it come this weekend and we'll see how it plays out all i know is this i been doing my scans here just a ton of those sales not no wordings nosales biotech's of being bit up again as the biotech index is gone topside over the last three days and today you would think may be get a pullback that they started a moth down the back up again and to be repetitive stopped getting a lot of questions about this just being end the month windowdressing preholiday could paid as of the second at that still sure i'd agree with that so what are you were the last hour the balk at the dow's up sixty seven s to p up seven nasdaq up ten nasdaq 100 only up four transports up sixty two better tell their these semiconductor the socks up five russell 2000 up about a.

kansas dow nasdaq russell gilead sciences eleven billion dollars three days
"gilead sciences" Discussed on WAFS Biz 1190

WAFS Biz 1190

02:11 min | 3 years ago

"gilead sciences" Discussed on WAFS Biz 1190

"The weekend will start with a big deal in the biotech industry gilead sciences bought kite pharma for twelve billion dollar in cash that was a twenty nine percent premium on where kite had been jeff i have to assume investors like this deal because gilead sciences wrote a twelve billion dollar cheque and their stock is still up ten percent on this deal he has a good week chris force several quarters maybe even a few years investors have been waiting for gilead to make an acquis russian that company even slow down its share buybacks and conserved cash we knew something big was come in and twelve billion dollars although it will not add to earnings it'll be neutral to the company's earnings for at least three years and then they help port to add to earnings the reason this kite pharma ticker kite still is right now is only an mental stage company at has more than twenty trials going but they're all early stage trials and they are pioneering immunotherapy to treat cancer patients and that's where you use the patient's own immune cells to fight the cancer in one instance you remove patients t cells and alter them and then put them back into the body to fight the cancer so it's fascinating technology that we all should help does very well now this week as well chris novartis had the first us approved immunotherapy cancer treatment approved by the fda just this week and that's when gilead shares really took off because they just made this acquisition shen in a leading company of that same sort of technology i was going to take his gilead scientists and christine hart juicers one of the host of our industry focus podcast made this point you talked about how they been conserving cash christine hit the point that kind of been a pretty steady and growing drumbeat from analysts assorted saying them like when he you going to buy someone when he can abide in other companies evidently it reminded me in the conference calls the past many quarters of apple for years like hey where's your watchwords your wearable and every quarter tim cut because like we're working and they did a good job i think at gilliat as well looks like they made a smart acquisition that deep type line for now and outrageous price but chris still what's going to drive.

gilead sciences cancer apple jeff chris novartis christine hart twelve billion dollar twelve billion dollars twenty nine percent ten percent three years
"gilead sciences" Discussed on KBNP AM 1410

KBNP AM 1410

01:51 min | 3 years ago

"gilead sciences" Discussed on KBNP AM 1410

"That's when gilead shares really took off because they just made this acquisition in a leading company of that same sort of technology i was gonna say coast gilead sciences uh in christine harshest who's one of the host of our industry focused plot just made this point uh you talked about how the been conserving cash christine that the point that the kind of been a pretty steady and growing drumbeat from analysts assorted saying them like when you can a buy someone when he kinda by another company definitely it reminded me in the conference calls the past many quarters of apple for years i came where's your watch where's your wearable and every quarter tim cooke because like we're working and he did a good job i think a gilead as well looks like they made a smart acquisition a deep pipeline for not an outrage ages price but chris still what's going to drive the stock the next three years is going to be the hepatitis market and the hiv market that still where killiadts hat is hanging last year wells fargo was discovered to have created two million fake checking accounts for customers upon further review by an outside auditor wells far go raised that number two three and a half million fake accounts and matt wall street was completely unfazed by this it's stock didn't drop it'll i know it's disappointing and i think josh brown who is a popular financial blogger he's unseemly season money managers agree analyst and i think he put it best on twitter yesterday he said is wells fargo was a community bank or any other small business they'd be driven out and their executives jailed i absolutely believe that but because it's wells fargo because it's a major bank major financial center and because of the number of accounts if you think about in the fees that were were taken in our so tiny world through the bank's total accounts in the banks will revenue i do expect officially it swept away and even three hundred eighty five million dollar find that was imposed a.

gilead sciences apple chris josh brown analyst twitter wells fargo christine tim cooke auditor three hundred eighty five mill three years
"gilead sciences" Discussed on Motley Fool Money

Motley Fool Money

01:41 min | 3 years ago

"gilead sciences" Discussed on Motley Fool Money

"I was her circus gilead sciences uh uh in christine hard juicers a one of the host of our industry focus parked us made this point um you talked about how the been conserving cash christine made the point that the kind of been a pretty steady and growing drumbeat from analysts assorted saying them like when he you can a by someone when he is going to buy another company evidently it reminded me in the conference calls the past many quarters of apple for years i came where's your watchwords your wearable and every quarter tim cooke because like we're working out and they did a good job i think a gilliat as well looks like they made a smart acquisition a deep pipeline for not an outrageous price but chris still what's going to drive the stock the next three years it's going to be the hepatitis market and the hiv market that still where killiadts hat is hanging last year wells fargo was discovered to have created two million fake checking accounts for customers upon further review by an outside auditor wells fargo raised that number two three and a half million fake accounts and matt wall street was completely unfazed by this it's stock didn't drop it'll i know it's disappointing and i think josh brown who is a popular financial blogger he's on seem he sees as money managers great analyst and i think he put it this on twitter yesterday he said if wells fargo was a community bank or any other small business they be driven out and their executives jailed i absolutely believe that but because it's wells fargo because it's a major bank major financial center and because of the number of accounts if you think about in the fees that were were taken in our so tiny realtor the bank's total accounts and in the bank's overall revenue.

gilead sciences apple chris josh brown analyst twitter christine tim cooke wells fargo auditor three years
"gilead sciences" Discussed on MarketFoolery

MarketFoolery

01:38 min | 3 years ago

"gilead sciences" Discussed on MarketFoolery

"For the tidy sum of twelve billion dollars in cash that is a nearly thirty percent premium off of kites closing price on friday and shares gilead sciences of a two and a half percent this morning chris name which at least on the surface that indicates to me that the reaction on wall street is they got a good price yes a now iit's people than waiting for guidance i insist to make an acquisition for so long for years and why is that by the way because they have so so much cash and as the company that did very very well initially in making a name for itself in treating hiv it then got nc of appetizers c business and very very well there but turns out when you're churn people of hepatitis c you're kind of going through your entire market and eliminating it as a sales there of very much slow down there is a lot of concern about where their next girth drivers will be and meanwhile they're just sitting on billions and billions in cash on the balance sheet they have something like twenty two billion dollars in cash and shortterm investments they have another fifteen billion dollars in longterm investments and they've had this for awhile as they continue to kick off more and more free cash flow him so you have your analysts sitting there looking at galyadh looking at the market out there which is filled with companies doing really interesting things in the biotech space and they're saying why have you guys not bought any one yet and so today when i see at up only two percent that's my reaction is why have it why is glad not up more this is what they've been waiting for so in some regards think the market might actually think good navy they overpaid here.

cash flow gilead sciences chris twenty two billion dollars fifteen billion dollars twelve billion dollars thirty percent two percent
"gilead sciences" Discussed on WAFS Biz 1190

WAFS Biz 1190

02:41 min | 4 years ago

"gilead sciences" Discussed on WAFS Biz 1190

"The drive and they went after gilead sciences uh a drug for hepatitis c yet uh which was a thousand dollars per pill but forty pills than you were cleared of hepatitis c and you didn't peter ra liver transplant and uh it was really a miracle type of a drug at the time and henry waxman here who has retired say only uh from the house the congressman in southern california he went after uh gilliat for the price they were charging for the drive the drug was named for faulty and he had congress get involved in wagging they're a grips the truck industry and that really put a halt to the advance in the biotech sector uh that's been it's kind of fat for the last two or three years you know once in awhile with awake uh but uh cell gene hasn't done any think for the last two or three years believe it or not it's a it's a dirt cheap stock i mean tell gene it's got a pc racial right now of 21 and on forward earnings its trading at about sixteen times slower during which is unheard of for a pharmaceutical so you know i like i like both of these stocks are like cell gene and i like luke burt belgian would be more appropriate for a more conservative investor i'm not making a recommendation here i've just throwing out a cup was named that uh are showing up on my radar i birds over there working through the benach roth excited such a great feeling when you see the horizon yeah and the surface of the ocean and we're still waiting for that and san diego by the way now we are not quite intel from the captain a little bit down south you know the guys that are turning left when they leave the harbour going down south of stuff it's just not around it might i did the the stairs that the beach the other day in the beach with green the water was ryan kollek class' and cold water does not good at all but usually when that clears out and the water turns blue boy competing well maybe maybe the water turns blue at blue for a question on now on bluebird dairy interestingly enough we have we ask folks to send in questions one of our app users days each has sent in a question he.

gilead sciences henry waxman the house congressman california congress luke burt belgian san diego three years thousand dollars